Patents by Inventor James A. Krom
James A. Krom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9999701Abstract: One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.Type: GrantFiled: February 6, 2017Date of Patent: June 19, 2018Assignee: Pulmonx CorporationInventors: Edward P. Ingenito, James A. Krom, Alexander Schwarz, Larry W. Tsai
-
Publication number: 20170239385Abstract: One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.Type: ApplicationFiled: February 6, 2017Publication date: August 24, 2017Inventors: Edward P. Ingenito, James A. Krom, Alexander Schwarz, Larry W. Tsai
-
Patent number: 9561301Abstract: One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.Type: GrantFiled: April 14, 2015Date of Patent: February 7, 2017Assignee: Aeris Therapeutics, LLCInventors: Edward P. Ingenito, James A. Krom, Alexander Schwarz, Larry W. Tsai
-
Publication number: 20150217020Abstract: One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.Type: ApplicationFiled: April 14, 2015Publication date: August 6, 2015Inventors: Edward P. Ingenito, James A. Krom, Alexander Schwarz, Larry W. Tsai
-
Patent number: 9006340Abstract: One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.Type: GrantFiled: May 21, 2013Date of Patent: April 14, 2015Assignee: Aeris Therapeutics, LLCInventors: Edward P. Ingenito, James A. Krom, Alexander Schwarz, Larry W. Tsai
-
Publication number: 20130325061Abstract: One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.Type: ApplicationFiled: May 21, 2013Publication date: December 5, 2013Applicant: Aeris Therapeutics, LLCInventors: Edward P. Ingenito, James A. Krom, Alexander Schwarz, Larry W. Tsai
-
Patent number: 8445589Abstract: One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.Type: GrantFiled: June 11, 2012Date of Patent: May 21, 2013Assignee: Aeris Therapeutics, LLCInventors: Edward P. Ingenito, James A. Krom, Alexander Schwarz, Larry W. Tsai
-
Publication number: 20120245627Abstract: One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.Type: ApplicationFiled: June 11, 2012Publication date: September 27, 2012Applicant: AERIS THERAPEUTICS, INC.Inventors: Edward P. Ingenito, James A. Krom, Alexander Schwarz, Larry W. Tsai
-
Patent number: 8198365Abstract: One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.Type: GrantFiled: May 8, 2008Date of Patent: June 12, 2012Assignee: Aeris Therapeutics, LLCInventors: Edward P. Ingenito, James A. Krom, Alexander Schwarz, Larry W. Tsai
-
Patent number: 7718738Abstract: A polymer nano-particle composition is provided, wherein the nano-particle includes a poly(alkenylbenzene) core and a surface layer including poly(conjugated diene). A method for self-assembly of the nano-particles is also provided. The polymer nano-particles are preferably less than about 100 nm in diameter.Type: GrantFiled: April 29, 2005Date of Patent: May 18, 2010Assignee: Bridgestone CorporationInventors: Georg G. A. Böhm, Xiaorong Wang, Chenchy Jeffrey Lin, James E. Hall, Sandra Warren, James A. Krom, Hajime Kondo, Koichi Morita
-
Publication number: 20080281352Abstract: One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.Type: ApplicationFiled: May 8, 2008Publication date: November 13, 2008Applicant: AERIS THERAPEUTICS, INC.Inventors: Edward P. Ingenito, James A. Krom, Alexander Schwarz, Larry W. Tsai
-
Patent number: 7241839Abstract: A reaction product is prepared by reacting a first polymer having pendant or terminal carboxyl or anhydride groups with a second polymer (e.g. elastomer) having an amine containing terminal group. The second polymer is anionically polymerized. The second polymer is functionalized by reacting the growing anionic chain end with an imine. Then a protic terminating agent terminates the growing chain end. The first and second polymers are reacted by mixing (desirably above their softening temperatures) and forming a blend with improved physical properties over a blend of similar polymers lacking a reactive amine group.Type: GrantFiled: August 17, 2005Date of Patent: July 10, 2007Assignee: Bridgestone CorporationInventors: James A. Krom, Xiaorong Wang
-
Patent number: 7056979Abstract: A reaction product is prepared by reacting a first polymer having pendant or terminal carboxyl or anhydride groups with a second polymer (e.g. elastomer) having an amine containing terminal group. The second polymer is anionically polymerized. The second polymer is functionalized by reacting the growing anionic chain end with an imine. Then a protic terminating agent terminates the growing chain end. The first and second polymers are reacted by mixing (desirably above their softening temperatures) and forming a blend with improved physical properties over a blend of similar polymers lacking a reactive amine group.Type: GrantFiled: June 12, 1998Date of Patent: June 6, 2006Assignee: Bridgestone CorporationInventors: James A. Krom, Xiaorong Wang
-
Publication number: 20040197264Abstract: One aspect of the present invention relates to a microsphere impregnated with a radioisotope that emits therapeutic &bgr;-particles and a radioisotope that emits diagnostic &ggr;-radiation; wherein the atomic number of the first radioisotope is not the same as the atomic number of the second radioisotope. In one preferred embodiment, the microsphere is composed of glass impregnated with 90Y as the source of the therapeutic &bgr;-emissions and 198Au as the source of the diagnostic &ggr;-emissions. Another aspect of the present invention relates to the preparation of a microsphere impregnated with a radioisotope that emits therapeutic &bgr;-particles and a radioisotope that emits diagnostic &ggr;-radiation; wherein the atomic number of the first radioisotope is not the same as the atomic number of the second radioisotope. In one preferred embodiment, a glass microsphere containing 90Y and 198Au is prepared by neutron activation of a glass microsphere comprising glass, 89Y and 197Au.Type: ApplicationFiled: April 4, 2003Publication date: October 7, 2004Inventors: Alexander Schwarz, James A. Krom
-
Patent number: 6630535Abstract: A composition comprising an elastomer, a filler, and a comb-like polymer, the comb-like polymer comprising a backbone and a plurality of side chains, the backbone having a length greater than or equal to the entanglement length, the side chains having a length greater than about 33% of the entanglement length, the backbone including at least one side chain per entanglement length, and the comb-like polymer having a Tg of less than −5° C.Type: GrantFiled: August 18, 2000Date of Patent: October 7, 2003Assignee: Bridgestone CorporationInventors: Terrence E. Hogan, James A. Krom, James E. Hall, Xiaorong Wang, Peyman Pakdel, William L. Hergenrother